BAFF-R CAR T cells for severe nerve and immune diseases
Part of Bones, joints & muscles, Brain & nervous system, Cancer, Eyes & vision, Immune system & allergy clinical trials.
This trial tests a new treatment using your own immune cells (called BAFF-R CAR T cells) for people with severe nerve and immune diseases that have not improved with standard medicines. These cells are designed to target and destroy certain immune cells that may be causing your illness.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a nerve or immune disease that has not improved after trying at least three different immune-suppressing medicines for over a year.
- You have had at least two relapses in the past year, or three relapses in the past two years, with at least one relapse in the last year.
- You must use birth control during treatment and for one year after, and you cannot donate sperm or become pregnant during that time.
- You have not taken rituximab in the last six months, or tocilizumab or eculizumab in the last three months.
- You do not have serious infections, liver or kidney problems, or other uncontrolled health conditions like high blood pressure or diabetes.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-stage trial uses a type of immune cell therapy (CAR-T cells) to treat severe autoimmune diseases that attack the nervous system, such as NMOSD, myasthenia gravis, CIDP, and multiple sclerosis. The goal is to see if this treatment can stop the immune system from damaging nerves when other treatments have failed.
This trial tests a new type of immune cell therapy (CAR T-cells) that targets CD19 and BCMA proteins on B cells. It is for people with certain neurological autoimmune diseases that have come back or not responded to standard treatments. The goal is to see if this therapy can help control the disease.
This trial tests a new kind of immunotherapy called CAR T-cells that are designed to find and attack a protein called BAFF-R on your lymphoma cells. It is for people with certain types of B-cell lymphoma that have not responded well to at least two earlier treatments.
This trial tests a new treatment using your own immune cells, modified to target a protein on B cells, for people with neuromyelitis optica spectrum disorder (NMOSD) that has not responded to standard treatments. It aims to reduce relapses and improve symptoms.
This Phase 1 study tests a new type of immune-cell therapy (CAR T cells) that targets BAFF-R to treat certain relapsed or refractory B-cell non-Hodgkin lymphoma (NHL). It aims to see if the treatment is safe and can shrink lymphoma in people who have tried prior therapies.
This trial tests a new type of immunotherapy called BAFF-R CAR-T cells for people with B-cell lymphoma that has come back or not responded to treatment, and whose cancer cells do not have the CD19 protein. The treatment uses your own immune cells, modified to target and kill the lymphoma cells.
Hear when a new Chronic Inflammatory Demyelinating Polyradiculoneuropathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.